Silymarin capsule in COVID-19

Phase 2

• Conditions: COVID-19 disease.; COVID-19; U07.1

• Registration Number: IRCT20180103038199N10
• Lead Sponsor: Mashhad University of Medical Sciences

Brief Summary

Not available

Detailed Description

Not available

Study Timeline

• Results First Posted: 1900-01-01
• Last Update Posted: 7 February 2022

Recruitment & Eligibility

• Status: Pending
• Sex: All
• Target Recruitment: 140

Inclusion Criteria

Outpatients with COVID-19
Confirmed with RT-PCR
SPO2 more than 90%
Age between 18 to 60 years old

Exclusion Criteria

Pregnant women
Breastfeeding women

Study & Design

• Study Type: interventional
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Time to recover from illness based on questionnaire. Timepoint: Before intervention and 3, 7 and 10 days after beginning the intervention. Method of measurement: Questionnaire.